« Back to News & Events

ITL Announces Positive Full Year Trading Update

ITL Health Group (“ITL”), an innovative global medical technology company, expects to announce very positive results for the financial year to 30 June 2017.

The second half results will show a significant improvement over the corresponding period in FY2016 and follow the high growth achieved in the first half in which revenue grew 11% to $17.5m, PBT increased 110% to $2.12m and EBITDA rose 69% to $2.7m.

Expected Full Year Results—Highlights:

  • Operating divisions have driven strong growth
  • Revenue of $35m ($31.1m FY 2016)
  • Profit Before Tax between $3.5m to $3.8m ($0.3m FY 2016)
  • EBITDA of $5.0m ($1.6m FY 2016)
  • Successful targeting of $3.3bn Blood Culture Testing market
  • February posted highest monthly revenue and profit in ITL’s 23 year history
  • $4m spent on R&D ($2m on MyHealthTest). $3m of the $4m has been expensed.


The improved Full Year results have been driven by continued growth in the operating divisions, ITL BioMedical and ITL Healthcare.

Bill Mobbs, Executive Chairman commented: “The financial year has seen a step change for ITL.  Our strategy to pursue high margin opportunities in emerging healthcare growth markets, and accelerate development of innovative patented products for the global healthcare markets has been a success.”

“We look forward to reporting positive Full Year results and the Board is looking to the remainder of 2017 and 2018 with confidence.”

Bill Mobbs

Executive Chairman

Read original article →